高级搜索
骨肉瘤术后辅助化疗远期疗效分析[J]. 肿瘤防治研究, 1990, 17(4): 219-221.
引用本文: 骨肉瘤术后辅助化疗远期疗效分析[J]. 肿瘤防治研究, 1990, 17(4): 219-221.
POSTOPERATIVE ADJUVANT CHEMOTHERAPY FOR OSTEOSARCOMA[J]. Cancer Research on Prevention and Treatment, 1990, 17(4): 219-221.
Citation: POSTOPERATIVE ADJUVANT CHEMOTHERAPY FOR OSTEOSARCOMA[J]. Cancer Research on Prevention and Treatment, 1990, 17(4): 219-221.

骨肉瘤术后辅助化疗远期疗效分析

POSTOPERATIVE ADJUVANT CHEMOTHERAPY FOR OSTEOSARCOMA

  • 摘要: 本文总结了我科自1978年开展大剂量氨甲喋呤及甲酰回氢叶酸钙解救(HDTX—CFR)疗法以来,对10例骨肉瘤病人术后进行辅助化疗的治疗效果。全组均采用HDMTX—CFR—VCR—ADM/CTX联合化疗,对7例共12疗程进行了MTX血药浓度监测。10例中有8例无病生存,无病中数生存期为56个月(43~99个月)2例手术后11、12个月死于肺转移。该方案毒性反应并不严重。

     

    Abstract: Since 1978, HDMTX—CF has been Performed inour hospital. Tsis Paper is brief summary based on 10 cases of postoperative osteosarcoma patients with adjurant chemotherapy. The mean age of the Patients was 21 years (range. 15—34) and the male to femaleratio was 2. 33: 1. This chemotherapy consisted of HDMT X—CFR—VCRADM/CTX. Total courses was 42, The dose was MTX of 1000—5000 mg per course.73.8%in dose was than 3000 mg per course. Total MTX dose was 4000-15000 mgeach patient. MTX concentrations were measured in serum. Eight patients are alive and disease—free with a median survival of 56 menths (range, 43-99). Two patients died of pulmonary metastases was not formidable. This study showed that HDMTX—CF is an effective treatment for postoperative osteosarcoma, can improve long—term survival and side—effects are acceptable.

     

/

返回文章
返回